Johnson & Johnson: 4 Acquisitions in Three Years, Spending Over $10 Billion to Build Cardiovascular Dominance - What are the Patient Interests Behind the Monopoly?

In the specialized field of medical devices, Johnson & Johnson has always been an industry leader. In recent years, Johnson & Johnson has continuously increased its investment in the medical device sector, and continued to enhance its competitiveness and market share in the field of cardiovascular disease treatment through a series of frequent mergers and acquisitions.

Specifically, on August 20 this year, Johnson & Johnson announced a major news that it acquired V-Wave, an Israeli cardiac medical device company, for a high price of 12.133 billion yuan. This is Johnson & Johnson's fourth large-scale acquisition in the cardiovascular field in the past three years, which fully demonstrates the company's ambition and strategic layout in this area.

Founded in 2009, V-Wave is focused on developing cardiovascular implantation technology for heart failure with reduced ejection fraction (HFrEF). Its flagship product, the V-Wave Ventura Shunt, is an innovative hourglass implant with a unique Venturi tube design that significantly improves blood transfer efficiency, reduces shunt size, and uses biocompatible materials to ensure long-term unobtrusivity. This product has received breakthrough device recognition from the US Food and Drug Administration (FDA) and CE certification in Europe in 2019 and 2020, respectively, and has attracted much attention from the industry.

The V-Wave Ventura Shunt is expected to be the first device of its kind to market and meet the unmet needs of the approximately 800,000 HFrEF patients in the United States each year, Johnson & Johnson said. This is one of the important reasons why Johnson & Johnson likes this product.

From a larger perspective, this acquisition is undoubtedly an important strategic deployment for Johnson & Johnson in the cardiovascular field. In the past three years, Johnson & Johnson has invested more than $30 billion in four cardiovascular mergers and acquisitions. These include Abiomed, which was acquired in 2022 for $16.6 billion, and Shockwave, which was acquired in April this year. It can be said that Johnson & Johnson is actively building its dominance in the global cardiovascular medical device field.

With the launch of innovative products such as V-Wave Ventura Shunt, and the integration of businesses from acquisitions such as Abiomed and Shockwave, Johnson & Johnson's cardiovascular revenues and profits are expected to grow further. We have reason to believe that in the near future, Johnson & Johnson can truly become a leader in the global medical device field.